aromatase inhibitor

Questions discussed in this category

What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?

Does node positivity affect your decision? Is there a role for predictive/prognostic test?

1 Answer available

Papers discussed in this category

Journal of the National Cancer Institute, 2005-09-07

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Cancer chemotherapy and pharmacology, 2009 Dec 03

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.

Related Topics